Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00445042 · ClinicalTrials.gov registry record · Phase 2
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
A Phase 2 study of Carcinoma, Renal Cell, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
- 1
- Study location
NCT00445042: Completed Phase 2 study of Carcinoma, Renal Cell, sponsored by The Methodist Hospital Research Institute.
NCT00445042 is a Phase 2 study of Carcinoma, Renal Cell that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 71 participants, below the 281-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00445042, a Phase 2 study of Carcinoma, Renal Cell, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and toxicity levels of Dose Escalated Sorafenib in the treatment of patients with renal cancer.
Conditions Studied
Interventions
- DRUG Sorafenib
Study Locations (1)
Texas
- Methodist Hospital - Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00445042 record still lists
NCT00445042 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 281-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which Sorafenib is the first listed.
NCT00445042 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00445042 about?
NCT00445042 is a clinical study titled "Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer". The purpose of this study is to determine the safety and toxicity levels of Dose Escalated Sorafenib in the treatment of patients with renal cancer.
What is the current status of trial NCT00445042?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2005-11. Estimated completion is 2008-10.
What conditions does trial NCT00445042 study?
This clinical trial studies the following conditions: Carcinoma, Renal Cell.
What interventions are being tested in trial NCT00445042?
The interventions under investigation include: Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00445042?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00445042 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Renal Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00445042's enrollment target sits among peer trials
71 19th of 34 higher than 16 of 34 other Carcinoma, Renal Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Renal Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous Dendritic Cell Vaccine in Kidney Cancer
RECRUITING · Phase 2
-
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
COMPLETED · Phase 2
-
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
COMPLETED · Phase 2
-
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
COMPLETED · Phase 2
-
Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia